A discussion panel with leading scientists at the forefront of substance use disorder and mental health research was held on September 1, 2022. The event was open to the public.

I. Welcome to CAN’s Inaugural Forum: Nancy Davis, Founder and President of CAN, joined by daughters Isabella and Mariella Rickel

II. Moderator and Introduction of Panel: Kurt Rasmussen, Ph.D., CSO Delix Therapeutics | CAN Scientific Advisory Board

III. Topics

1. Evaluation of a New FDA-Approved Non-Narcotic Medication, Suvorexant (Belsomra), for the Treatment of Insomnia During Opioid Withdrawal and Directly Reduced the Severity of Withdrawal and Craving, With No Identified Risk for Misuse: Kelly E. Dunn, Ph.D., Johns Hopkins School of Medicine
2. Breaking The Cycle of Opioid Use Disorder with Ibogaine: Deborah C. Mash, Ph.D., University of Miami School of Medicine
3. Psychedelics in The Treatment of Substance Use Disorders: Matthew W. Johnson, Ph.D., Johns Hopkins University School of Medicine
4. Development of Nasal Nalmefene for Opioid Overdose: Roger Crystal, MD, President, Chief Executive Officer, Opiant Pharmaceuticals, Inc.
5. Current Research - Novel "Chemical Sensing” Mechanism That Detects the Presence of Opioids and Other Addictive Drugs in the Body Before They Reach the Brain, Which is Involved in Controlling Subsequent Addiction-Related Actions of the Drugs Paul J. Kenny, Ph.D., Mount Sinai
6. Loss and Living with Substance Use Disorder: Jodi Barber and Jason Wahler
7. Development of A Single Use Medication for the Treatment of Substance Use Disorder: Courtney Miller, Ph.D., UF Scripps Biomedical Research
8. The Risks of Taking An Opioid: Chris Evans Ph.D., Stefan Hatos Professor, UCLA
9. Kappa Opioid Receptors As a Target for Treating Opioid Use Disorder: Catherine M. Cahill, Ph.D., UCLA
10. The Connection Between Mental Health and Substance Use Disorder: Adam Kaplin, M.D, Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals

IV. Lightning Round: Answers to Submitted Questions

V. Conclusion and Thank You by Nancy Davis